{"transactions":[{"id":2825108,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":142076,"kind":"person","name":"Wessels Gregory S.","position":1,"cik":"0001824615","reported_name":"Wessels Gregory S.","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-03-02T00:10:17.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":66000,"derivative":{"exercise_price":6,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001140361-21-006735","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006735/form4.xml","form_type":"4"}},{"id":2825107,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":142076,"kind":"person","name":"Wessels Gregory S.","position":1,"cik":"0001824615","reported_name":"Wessels Gregory S.","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-02T00:10:17.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 5,333 shares on February 25, 2022, (ii) 5,333 shares on February 25, 2023 and 5,334 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001140361-21-006735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006735/form4.xml","form_type":"4"}},{"id":3026523,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":142076,"kind":"person","name":"Wessels Gregory S.","position":1,"cik":"0001824615","reported_name":"Wessels Gregory S.","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2020-09-18T21:05:08.000Z","date":"2020-09-16","kind":"grant","acquired":true,"shares":14700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on September 16, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":14700,"derivative":{"exercise_price":28.75,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":14700},"source":{"system":"sec-edgar","filing":"0000905148-20-001030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000090514820001030/form4.xml","form_type":"4"}}]}